Abstract:Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are related intestinal L-cell derived secretory products. GLP-1 has been extensively studied in terms of its influence on metabolism, but less attention has been devoted to GLP-2 in this regard. The current study compares the effects of these proglucagon-derived peptides on pancreatic beta-cell function, as well as on glucose tolerance and appetite. The insulin secretory effects of GLP-1 and GLP-2 (10−12–10−6 M) were investigated in BRIN-BD11 beta-cells as well as isolated mouse islets, with the impact of test peptides (10 nM) on real-time cytosolic cAMP levels further evaluated in mouse islets. The impact of both peptides (10−8–10−6 M) on beta-cell growth and survival was also studied in BRIN BD11 cells. Acute in vivo (peptides administered at 25 nmol/kg) glucose homeostatic and appetite suppressive actions were then examined in healthy mice. GLP-1, but not GLP-2, concentration dependently augmented insulin secretion from BRIN-BD11 cells, with similar observations made in isolated murine islets. In addition, GLP-1 substantially increased [cAMP]cyt in islet cells and was significantly more prominent than GLP-2 in this regard. Both GLP-1 and GLP-2 promoted beta-cell proliferation and protected against cytokine-induced apoptosis. In overnight fasted healthy mice, as well as mice trained to eat for 3 h per day, the administration of GLP-1 or GLP-2 suppressed appetite. When injected conjointly with glucose, both peptides improved glucose disposal, which was associated with enhanced glucose-stimulated insulin secretion by GLP-1, but not GLP-2. To conclude, the impact of GLP-1 and GLP-2 on insulin secretion is divergent, but the effects of beta-cell signaling and overall health are similar. Moreover, the peripheral administration of either hormone in rodents results in comparable positive effects on blood glucose levels and appetite.

Research Progress in the Effect Evaluation of GLP1-1 Agonists

Effect of glucagon-like peptide-1 for the treatment of diabetes mellitus

Progress in the investigation of GLP-1 receptor agonists and DPP-Ⅳ inhibitors

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

Clinical and Basic Studies of GLP-1 Receptor Agonists for the Treatment of Diabetes in China

The clinical experience of GLP-1 receptor agonist drugs

Progress of extrapancreatic effects by glucagon-like peptide-1

Glucagon-like Peptide 1 and Its Derivatives in the Treatment of Diabetes-preclinical and Clinical Results

Research Progress of Glucagon-Like Peptide-1 in the Treatment of Type 2 Diabetes Mellitus

Latest Progress in the Drug Development of Glucagon-Like Peptide 1 Analogues

Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists

Study Progression of GLP-1 Analogues in Type 1 Diabetes and Islet Transplant

GLP-1, a powerful physiological incretin: an update.

Comparative Effects of GLP-1 and GLP-2 on Beta-Cell Function, Glucose Homeostasis and Appetite Regulation

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists

Small-molecule GLP-1 Secretagogs: Challenges and Recent Advances.

The Cardiovascular Effect of Glucagon-like Peptide-1 Receptor Agonists

The Research Progress of DPP-4 Inhibitors.

Protective effects of glucagon-like polypeptide 1(GLP-1),GLP-1 mimetics and dipeptidyl peptidase IV on pancreatic function